Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 101–200 of 1,676
2023 Chinese guideline for lipid management
Li, J.-J., Zhao, S.-P., Zhao, D., Lu, G.-P., Peng, D.-Q., Liu, J., Chen, Z.-Y., Guo, Y.-L., Wu, N.-Q., Yan, S.-K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190934 · Cited by 223
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial
Panahi, Y., Khalili, N., Sahebi, E., Namazi, S., Reiner, Ž., Majeed, M., & Sahebkar, A. (2017) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2017.05.006 · Cited by 220
Sanchez-Rodriguez, E., Egea-Zorrilla, A., Plaza-Díaz, J., Aragón-Vela, J., Muñoz-Quezada, S., Tercedor-Sánchez, L., & Abadia-Molina, F. (2020) · Nutrients · doi:10.3390/nu12030605 · Cited by 214
“Vitamin B3 might increase all-cause mortality, which was probably associated with its adverse effects on glycemic response [166,167].”
Background2018 Guidelines for the management of dyslipidemia
Rhee, E.-J., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, H. J., Choi, S., et al. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.188 · Cited by 213
“Furthermore, the “Effects of extended-release niacin with laropiprant in high-risk patients,” HPS2-THRIVE study reported that adding niacin and facial flushing inhibitor laropiprant to statin therapy could not reduce major cardiovascular events and actually led to an increase of adverse reactions, such as myopathy, li…”
BackgroundXiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
Varbo, A., Freiberg, J. J., & Nordestgaard, B. G. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.234146 · Cited by 209
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome
Murphy, S. A., Cannon, C. P., Blazing, M. A., Giugliano, R. P., White, J. A., Lokhnygina, Y., Reist, C., Im, K., Bohula, E. A., Isaza, D., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.077 · Cited by 205
“(17,18), torcetrapib (19), and dalcetrapib (20).”
Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
Giugliano, R. P., & Sabatine, M. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.001 · Cited by 199
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Ganda, O. P., Bhatt, D. L., Mason, R. P., Miller, M., & Boden, W. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.061 · Cited by 195
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Banach, M., Stulc, T., Dent, R., & Toth, P. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.075 · Cited by 197
Optimizing cholesterol treatment in patients with muscle complaints
Rosenson, R. S., Baker, S., Banach, M., Borow, K. M., Braun, L. T., Bruckert, E., Brunham, L. R., Catapano, A. L., Elam, M. B., Mancini, G. B. J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.752 · Cited by 193
2018 Guidelines for the Management of Dyslipidemia in Korea
Rhee, E.-J., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, H. J., Choi, S., et al. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.78 · Cited by 192
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 192
Cheeley, M. K., Saseen, J. J., Agarwala, A., Ravilla, S., Ciffone, N., Jacobson, T. A., Dixon, D. L., & Maki, K. C. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.05.068 · Cited by 197
Michael Gibson, C., Korjian, S., Tricoci, P., Daaboul, Y., Yee, M., Jain, P., Alexander, J. H., Steg, P. G., Lincoff, A. M., Kastelein, J. J. P., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.025687 · Cited by 191
Dyslipidemia in patients with chronic kidney disease
Hager, M. R., Narla, A. D., & Tannock, L. R. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9402-z · Cited by 186
“Furthermore, recent evidence has not found any benefit to statin + niacin combinations [55, 56].”
Elam, M. B., Ginsberg, H. N., Lovato, L. C., Corson, M., Largay, J., Leiter, L. A., Lopez, C., O’Connor, P. J., Sweeney, M. E., Weiss, D., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4828 · Cited by 185
Effects of curcumin on HDL functionality
Ganjali, S., Blesso, C. N., Banach, M., Pirro, M., Majeed, M., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.008 · Cited by 186
Nicholls, S. J., Andrews, J., Kastelein, J. J. P., Merkely, B., Nissen, S. E., Ray, K. K., Schwartz, G. G., Worthley, S. G., Keyserling, C., Dasseux, J.-L., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2121 · Cited by 185
Bhatt, D. L., Steg, P. G., Brinton, E. A., Jacobson, T. A., Miller, M., Tardif, J., Ketchum, S. B., Doyle, R. T., Murphy, S. A., Soni, P. N., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22692 · Cited by 183
Gencer, B., Kronenberg, F., Stroes, E. S., & Mach, F. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx033 · Cited by 184
“statin.(35,48) New emerging therapies, such as apo(B) antisense oligonucleotides and PCSK9 inhibitors, have already reported significant”
BackgroundHypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
Tenenbaum, A., Klempfner, R., & Fisman, E. Z. (2014) · Cardiovascular Diabetology · doi:10.1186/preaccept-2085133501150912 · Cited by 186
“niacin (using extended-release niacin; AIM-HIGH [127] and HPS2-THRIVE [128]) were done on the background”
BackgroundMethodAPOA1: a Protein with Multiple Therapeutic Functions
Cochran, B. J., Ong, K.-L., Manandhar, B., & Rye, K.-A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00906-7 · Cited by 179
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
Nicholls, S. J., Puri, R., Ballantyne, C. M., Jukema, J. W., Kastelein, J. J. P., Koenig, W., Wright, R. S., Kallend, D., Wijngaard, P., Borgman, M., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2112 · Cited by 174
High-Density Lipoprotein Cholesterol and Mortality: Too Much of a Good Thing?
Hamer, M., O’Donovan, G., & Stamatakis, E. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310587 · Cited by 171
Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations
Noels, H., Lehrke, M., Vanholder, R., & Jankowski, J. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00423-5 · Cited by 173
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 172
High-Density Lipoprotein Anti-Inflammatory Capacity and Incident Cardiovascular Events
Jia, C., Anderson, J. L. C., Gruppen, E. G., Lei, Y., Bakker, S. J. L., Dullaart, R. P. F., & Tietge, U. J. F. (2021) · Circulation · doi:10.1161/circulationaha.120.050808 · Cited by 170
Nicholls, S. J., Lincoff, A. M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23055 · Cited by 167
“Two large trials of niacin, delivered in either an extended release formulation or in combination with a prostanoid receptor antagonist, both delivery methods intended to improve tolerance, failed to reduce cardiovascular events in statintreated patients.(26,27)”
BackgroundStatins and PCSK9 inhibitors: A new lipid-lowering therapy
Gallego-Colon, E., Daum, A., & Yosefy, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173114 · Cited by 156
2017 Taiwan lipid guidelines for high risk patients
Li, Y.-H., Ueng, K.-C., Jeng, J.-S., Charng, M.-J., Lin, T.-H., Chien, K.-L., Wang, C.-Y., Chao, T.-H., Liu, P.-Y., Su, C.-H., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.11.013 · Cited by 157
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Archives of Medical Science · doi:10.5114/aoms/141941 · Cited by 186
Arvanitis, M., & Lowenstein, C. J. (2023) · Annals of Internal Medicine · doi:10.7326/aitc202306200 · Cited by 190
Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)
Tsimikas, S., Moriarty, P. M., & Stroes, E. S. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.051 · Cited by 154
The role of lipoprotein (a) in chronic kidney disease
Hopewell, J. C., Haynes, R., & Baigent, C. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r083626 · Cited by 172
HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology
Rosenson, R. S., Brewer, H. B., Barter, P. J., Björkegren, J., Chapman, M. J., Gaudet, D., Kim, D. S., Niesor, E. J., Rye, K., Sacks, F. M., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.115 · Cited by 160
High-Density Lipoprotein Function and Dysfunction in Health and Disease
Chiesa, S. T., & Charakida, M. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-06846-w · Cited by 165
Sahebkar, A., Reiner, Ž., Simental‐Mendía, L. E., Ferretti, G., & Cicero, A. F. G. (2016) · Metabolism · doi:10.1016/j.metabol.2016.08.007 · Cited by 157
Mechanisms and Treatment of Dyslipidemia in Diabetes
Bahiru, E. M., Hsiao, R., Philipson, D. J., & Watson, K. E. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01455-w · Cited by 183
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease
Schmidt, A. F., Hunt, N. B., Gordillo-Marañón, M., Charoen, P., Drenos, F., Kivimaki, M., Lawlor, D. A., Giambartolomei, C., Papacosta, O., Chaturvedi, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25703-3 · Cited by 142
Stiekema, L. C. A., Stroes, E. S. G., Verweij, S. L., Kassahun, H., Chen, L., Wasserman, S. M., Sabatine, M. S., Mani, V., & Fayad, Z. A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy862 · Cited by 141
Nazir, S., Jankowski, V., Bender, G., Zewinger, S., Rye, K.-A., & van der Vorst, E. P. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.006 · Cited by 140
Reducing LDL with PCSK9 inhibitors—the clinical benefit of lipid drugs
Everett, B. M., Smith, R. J., & Hiatt, W. R. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1508120 · Cited by 112
Natural approaches in metabolic syndrome management
Patti, A. M., Al-Rasadi, K., Giglio, R. V., Nikolic, D., Mannina, C., Castellino, G., Chianetta, R., Banach, M., Cicero, A. F., Lippi, G., et al. (2018) · Archives of Medical Science · doi:10.5114/aoms.2017.68717 · Cited by 139
“Previously available randomized clinical trial data assessing the clinical efficacy of niacin have been challenged by results from AIM-HIGH and HPS-2 THRIVE, which failed to demonstrate a reduction in CVD event incidence in patients with established CVD treated with niacin as an adjunct to intensive simvastatin therap…”
ResultZhong, G.-C., Huang, S.-Q., Peng, Y., Wan, L., Wu, Y.-Q.-L., Hu, T.-Y., Hu, J.-J., & Hao, F.-B. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320914756 · Cited by 136
Varbo, A., Freiberg, J. J., & Nordestgaard, B. G. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.279463 · Cited by 133
HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role
Casula, M., Colpani, O., Xie, S., Catapano, A. L., & Baragetti, A. (2021) · Cells · doi:10.3390/cells10081869 · Cited by 162
“However, in the AIM-HIGH [26] and the HPS2-THRIVE trials [27], primarily designed to evaluate the effect of niacin added to a background statin on cardiovascular outcomes, the treatment with niacin increased HDL-C levels but did not lower the risk of cardiovascular events.”
MethodWilson, P. W. F., Polonsky, T. S., Miedema, M. D., Khera, A., Kosinski, A. S., & Kuvin, J. T. (2019) · Circulation · doi:10.1161/cir.0000000000000626 · Cited by 135
Trinder, M., Walley, K. R., Boyd, J. H., & Brunham, L. R. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313381 · Cited by 133
Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis
Harrison, S. C., Holmes, M. V., Burgess, S., Asselbergs, F. W., Jones, G. T., Baas, A. F., van ’t Hof, F. N., de Bakker, P. I. W., Blankensteijn, J. D., Powell, J. T., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4293 · Cited by 131
Trends in lipid-modifying agent use in 83 countries
Blais, J. E., Wei, Y., Yap, K. K. W., Alwafi, H., Ma, T.-T., Brauer, R., Lau, W. C. Y., Man, K. K. C., Siu, C. W., Tan, K. C. B., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.016 · Cited by 131
Kirkland, J. B., & Meyer‐Ficca, M. L. (2018) · Advances in food and nutrition research · doi:10.1016/bs.afnr.2017.11.003 · Cited by 165
Vegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials
Koch, C. A., Kjeldsen, E. W., & Frikke-Schmidt, R. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad211 · Cited by 134
Proof That Lower Is Better — LDL Cholesterol and IMPROVE-IT
Jarcho, J. A., & Keaney, J. F. (2015) · New England Journal of Medicine · doi:10.1056/nejme1507041 · Cited by 131
Lipoprotein apheresis to treat elevated lipoprotein (a)
Waldmann, E., & Parhofer, K. G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r056549 · Cited by 131
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues
Sherratt, S. C. R., Libby, P., Budoff, M. J., Bhatt, D. L., & Mason, R. P. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01075-x · Cited by 129
Determining When to Add Nonstatin Therapy
Robinson, J. G., Huijgen, R., Ray, K. K., Persons, J. E., Kastelein, J. J. P., & Pencina, M. J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.928 · Cited by 137
Preston Mason, R. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0762-1 · Cited by 129
Rosenzweig, J. L., Bakris, G. L., Berglund, L. F., Hivert, M.-F., Horton, E. S., Kalyani, R. R., Murad, M. H., & Vergès, B. L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01338 · Cited by 126
The Effect of Inflammation and Infection on Lipids and Lipoproteins
Feingold, K. R., & Grünfeld, C. (2015) · Europe PMC (PubMed Central) · Cited by 139
Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization
Zhu, T., & Goodarzi, M. O. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab757 · Cited by 126
Nichols, G. A., Philip, S., Reynolds, K., Granowitz, C. B., & Fazio, S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13537 · Cited by 125
“However, the ADA does not currently recommend treating hypertriglyceridaemia for CVD risk reduction because clinical trials of agents that lower TG, specifically fenofibrates and niacin, have failed to demonstrate a reduction in CVD outcomes.(25,30,31) The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD…”
BackgroundFerrell, M., Wang, Z., Anderson, J. T., Li, X. S., Witkowski, M., DiDonato, J. A., Hilser, J. R., Hartiala, J., Haghikia, A., Čajka, T., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02793-8 · Cited by 141
Mhaimeed, O., Burney, Z. A., Schott, S. L., Kohli, P., Marvel, F. A., & Martin, S. S. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100649 · Cited by 124
“Niacin is a water-soluble vitamin which primarily increases HDL-C while modestly reducing LDL-C and TG, which similarly showed benefit as a monotherapy but not as an adjunct to statins [82,83].”
BackgroundWriting Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety
Snaidr, V. A., Damian, D. L., & Halliday, G. M. (2019) · Experimental Dermatology · doi:10.1111/exd.13819 · Cited by 121
Management of diabetic dyslipidemia: An update
Jialal, I., & Singh, G. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i5.280 · Cited by 120
Niacin for primary and secondary prevention of cardiovascular events
Schandelmaier, S., Briel, M., Saccilotto, R. T., Olu, K. K., Arpagaus, A., Hemkens, L. G., & Nordmann, A. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009744.pub2 · Cited by 142
Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
Suh, S. H., & Kim, S. W. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0067 · Cited by 156
Kannt, A., Pfenninger, A., Teichert, L., Tönjes, A., Dietrich, A., Schön, M. R., Klöting, N., & Blüher, M. (2015) · Diabetologia · doi:10.1007/s00125-014-3490-7 · Cited by 118
Sacks, F. M., & Jensen, M. K. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.307025 · Cited by 117
Stiekema, L. C. A., Prange, K. H. M., Hoogeveen, R. M., Verweij, S. L., Kroon, J., Schnitzler, J. G., Dzobo, K. E., Cupido, A. J., Tsimikas, S., Stroes, E. S. G., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa171 · Cited by 118
Toth, P. P., Granowitz, C., Hull, M., Liassou, D., Anderson, A., & Philip, S. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008740 · Cited by 117
Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges
Petroni, M. L., Brodosi, L., Marchignoli, F., Sasdelli, A. S., Caraceni, P., Marchesini, G., & Ravaioli, F. (2021) · Nutrients · doi:10.3390/nu13082748 · Cited by 116
“Similar re-sults were provided by the large trial of combination treatment with niacin plus laropiprant [111], where niacin treatment (2 g/day for a median of 3.9 years) was associated with an increased incidence of de novo T2D (rate ratio, 1.32; 95% CI 1.16–1.51) and deterioration in metabolic…”
ResultInfluentialNicholls, S. J., Ruotolo, G., Brewer, H. B., Kane, J. P., Wang, M.-D., Krueger, K. A., Adelman, S. J., Nissen, S. E., & Rader, D. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.013 · Cited by 114
Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease
Kohan, A. B. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000136 · Cited by 113
The pharmacological management of metabolic syndrome
Rask Larsen, J., Dima, L., Correll, C. U., & Manu, P. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1429910 · Cited by 113
“[87] found no benefit but significant excess in serious EXPERT REVIEW OF CLINICAL PHARMACOLOGY 401”
BackgroundTreatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
Zodda, D., Giammona, R., & Schifilliti, S. (2018) · Pharmacy · doi:10.3390/pharmacy6010010 · Cited by 112
“Extended-release niacin was tested in combination with laropiprant, an antagonist of the prostaglandin D2 receptor DP1 that has been shown to reduce flushing in up to two-thirds of patients, but was withdrawn due to increased risk of non-fatal, but serious side effects after preliminary data from a large, long-term st…”
Warden, B. A., Guyton, J. R., Kovacs, A. C., Durham, J. A., Jones, L. K., Dixon, D. L., Jacobson, T. A., & Duell, P. B. (2023) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.09.001 · Cited by 111
“82 , 83 The LDL-C-lowering efficacy is modest, but cholestyramine monotherapy is also proven to reduce the risk of cardiovascular events.”
Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment
Jenkins, D. J. A., Spence, J. D., Giovannucci, E. L., Kim, Y.-I., Josse, R. G., Vieth, R., Sahye-Pudaruth, S., Paquette, M., Patel, D., Blanco Mejia, S., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.619 · Cited by 110
High density lipoprotein cholesterol and cancer: Marker or causative?
Pirro, M., Ricciuti, B., Rader, D. J., Catapano, A. L., Sahebkar, A., & Banach, M. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.06.001 · Cited by 116
Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis
Yarmolinsky, J., Bonilla, C., Haycock, P., Langdon, R., Lotta, L. A., Langenberg, C., Relton, C. L., Lewis, S. J., Evans, D. M., Smith, G. D., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy081 · Cited by 116
“The alignment of Mendelian randomization with SELECT estimates mirrors the concordance of Mendelian randomization findings with other large, phase III trials; including adverse effects of elevated LDL cholesterol on coronary heart disease (30, 31) and statin use with type 2 diabetes (32, 33); and null effects of secre…”
ResultThe Changing Face of HDL and the Best Way to Measure It
Karathanasis, S. K., Freeman, L. A., Gordon, S. M., & Remaley, A. T. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.257725 · Cited by 109
Fan, Q., Maranville, J., Fritsche, L. G., Sim, X., Cheung, C. M. G., Chen, L. J., Gorski, M., Yamashiro, K., Ahn, J., Laude, A., et al. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx189 · Cited by 118
The Role of Lipids and Lipoproteins in Atherosclerosis
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W., Doran, A. C., & Vickers, K. C. (2015) · Europe PMC (PubMed Central) · Cited by 153
O'Donoghue, M. L., G. López, J. A., Knusel, B., Gencer, B., Wang, H., Wu, Y., Kassahun, H., & Sabatine, M. S. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.05.004 · Cited by 109
Verma, H., & Garg, R. (2017) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12454 · Cited by 121
“The overall risk of CVD associated morbidity and motility in T2D involves a complex interplay between these factors ((8,9)).”
Background2023 China Guidelines for Lipid Management
Li, J., Zhao, S., Zhao, D., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2023.09.008 · Cited by 129
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
MethodHuh, J. H., Han, K.-D., Cho, Y. K., Roh, E., Kang, J. G., Lee, S. J., & Ihm, S.-H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01667-6 · Cited by 106
“We demonstrated that remnant-C was the major cholesterol fraction contributor to the development of MI and stroke in patients with T2D without a history of ASCVD.”
BackgroundInfluentialVinci, P., Girolamo, F. G. D., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Altamura, N., Pirulli, A., Zaccari, M., Biasinutto, C., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20186721 · Cited by 139
Nicholls, S. J., Puri, R., Wolski, K., Ballantyne, C. M., Barter, P. J., Brewer, H. B., Kastelein, J. J. P., Hu, B., Uno, K., Kataoka, Y., et al. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0146-z · Cited by 107
Orringer, C. E., Jacobson, T. A., & Maki, K. C. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.10.014 · Cited by 103
Nichols, G. A., Philip, S., Reynolds, K., Granowitz, C. B., & Fazio, S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00470 · Cited by 102
Regulation of NAD+ metabolism in aging and disease
Chu, X., & Raju, R. P. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154923 · Cited by 115
Clinical Trial Design for Lipoprotein(a)-Lowering Therapies
Malick, W. A., Goonewardena, S. N., Köenig, W., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.033 · Cited by 116
Kastelein, J. J. P., Besseling, J., Shah, S., Bergeron, J., Langslet, G., Hovingh, G. K., Al‐Saady, N., Koeijvoets, M., Hunter, J. A., Johnson‐Levonas, A. O., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62115-2 · Cited by 102
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.